Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, is in an ideal position to be “profitable” in 2023. That was the outlook reported in a shareholder letter released by JUPW CEO Brian John. The letter noted 2022 highlights, such as the company becoming the second U.S. equity to dual list on Upstream, a revolutionary trading app for digital securities and NFTs, and JUPW’s SRM Entertainment division submitting a confidential registration statement to the SEC on a key step on its journey to becoming an independently traded NASDAQ company. The letter also noted that Jupiter Wellness had expanded to the Indian market with its Photofirst product and had seen its NoStingz sunscreen register record sales during the January Surf Expo in Orlando. In addition, the company reported record revenues in 2022 with plans for even more success in 2023, based on a license agreement with Taisho Pharmaceutical Co. Ltd. to sell Minoxidil Booster and Photocil in the Japanese market and Sanpellegrino Cosmetics Pvt Ltd & Cosmofix Technovation Pvt Ltd. in the Indian market and 31 other countries. The letter added that Jupiter will be developing revolutionary prescription products through an exclusive licensing agreement with Rejoy Inc. “As we look forward to 2023, the entire executive team at Jupiter Wellness is grateful for your support and commitment to our success,” wrote Jupiter Wellness CEO Brian John in the shareholder letter. “With your help, we have been able to lay the groundwork for even greater financial growth, monetization of our clinical trial programs, improvements in profitability, and an increase in shareholder value.”

To view the full press release, visit https://ibn.fm/4Xliv

About Jupiter Wellness Inc.

Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, eczema, burns and sexual wellness. Revenue is generated through the sales of OTC and consumer products, contract research agreements and licensing royalties. For additional information about this company, please visit www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.